97485-07-9

Upstream product

• 405-39-0 N,N'-di-[(phenylmethoxy)carbonyl]-L-lysine 
• 27894-50-4 methyl (2S)-2-amino-6-{[(benzyloxy)carbonyl]amino}hexanoate hydrochloride 
• 13673-52-4 Z-Lys(Z)-OPcp 
• 1155-64-2 N₆-[(benzyloxy)carbonyl]-L-lysine 
• 501-53-1 benzyl chloroformate 
• 24498-31-5 (S)-methyl 2-amino-6-(benzyloxycarbonylamino)hexanoate 
• 1158-35-6 N^ε-benzyloxycarbonyl-D-lysine methyl ester hydrochloride 
• 97485-06-8 (Z)-D-Lys(Z)-OPcp 
• 405-39-0 N^α,N^ε-Bis(benzyloxycarbonyl)-D-lysine 
• 1273583-84-8 C₂₇H₃₆N₄O₇ 

Downstream Products

• 614-02-8 N⁶-[(benzyloxy)carbonyl]-N²-{N ²,N⁶-bis[(benzyloxy)carbonyl]-L-lysyl}-L-lysine 
• 108432-87-7 N⁶-benzyloxycarbonyl-N²-(N²,N⁶-bis-benzyloxycarbonyl-L-lysyl)-L-lysine hydrazide 
• 1273583-91-7 C₃₆H₄₃N₄O₉^(1-)*Na⁽¹⁺⁾ 
• 1273583-93-9 C₄₁H₅₄N₆O₁₀ 
• 1346119-13-8 C₆₅H₉₉N₅O₁₂ 
• 1346119-11-6 C₆₅H₁₀₁N₇O₁₀ 
• 614-02-8 N⁶-benzyloxycarbonyl-N²-(N²,N⁶-bis-benzyloxycarbonyl-L-lysyl)-D-lysine 
• 97485-08-0 N⁶-benzyloxycarbonyl-N²-(N²,N⁶-bis-benzyloxycarbonyl-L-lysyl)-D-lysine hydrazide 
• 122701-29-5 N⁶-benzyloxycarbonyl-N²-[N⁶-benzyloxycarbonyl-N²-(N²,N⁶-bis-benzyloxycarbonyl-L-lysyl)-L-lysyl]-L-lysine methyl ester 
• 120207-81-0 N⁶-benzyloxycarbonyl-N²-[N⁶-benzyloxycarbonyl-N²-(N²,N⁶-bis-benzyloxycarbonyl-L-lysyl)-L-lysyl]-L-lysine 

Relevant academic research and scientific papers

CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO

In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self- immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO

In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY

Here described are compounds of formula I: wherein R1 and R2 is independently selected from a group consisting of C10 to C18 alkyl, C12 to C18 alkenyl, and oleyl group; wherein R3 and R4 are independently selected from a group consisting of C1 to C6 alkyl, and C2 to C6 alkanol; wherein X is selected from a group consisting of -CH2-, -S-, and -O- or absent; wherein Y is selected from -(CH2)n, -S(CH2)n, -O(CH2)n-, thiophene, -SO2(CH2)n-, and ester, wherein n = 1 -4; wherein a = 1 -4; wherein b=l -4; wherein c=l-4; and wherein Z is a counterion; and compounds consisting of the structure (targeting molecule)m-linker-(targeting molecule)n, wherein the targeting molecule is a retinoid or a fat soluble vitamin having a specific receptor on the target cell; wherein m and n are independently 0, 1, 2 or 3; and wherein the linker comprises a polyethylene glycol (PEG) or PEG-like molecule, as well as compositions and pharmaceutical formulations including one or both of these compounds which are useful for the delivery of therapeutic agents; and methods of using these compositions and pharmaceutical formulations.

Synthesis and transfection efficiency of cationic oligopeptide lipids: Role of linker

In the design of new cationic lipids for gene transfection, the chemistry of linkers is widely investigated from the viewpoint of biodegradation and less from their contribution to the biophysical properties. We synthesized two dodecyl lipids with glutami

Anionic activators for differential sensing with cell-penetrating peptides

The design, synthesis, and evaluation of small peptides with one to three negative charges and one to three hydrazides as key components of membrane-based synthetic sensing systems are reported. Their spontaneous reaction with hydrophobic aldehydes or ket

SYNTHESIS OF NEW BRANCHED POLYPEPTIDES WITH POLY(LYSINE)BACK BONE

New analogues of branched polypeptides were synthesised for a further, more detailed study of the influence of the side chain terminating amino acids, particularly the hydrophobic character, configuration and the number of these amino acids, on the conformation and biological properties of the polymers.The folowing amino acids were coupled to poly(L-Lys-(DL-Alam)) in suitably protected and activated forms to study the above mentioned aspects: L-Nle, L-Ile, L-Val, L-Phe, D-Phe, D-Leu, D-Tyr, D-His, L-Glu, D-Glu, L-Lys, D-Lys and additionally the L-Glu-L-Glu, D-Glu-D-Glu, L-Lys-L-Lys and D-Lys-D-Lys dipeptides.The protected and purified end products were freezedried and characterized by various methods.